Pulmonx Corporation LUNG
Pulmonx Corporation (Nasdaq: LUNG) is a respiratory medical device company. Its next catalyst on record is Revenue milestone: First $10.0M additional loan draw becomes available if revenue reaches $92.5M for any trailing twelve-month period (Q3 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Revenue milestone — First $10.0M additional loan draw becomes available if revenue reaches $92.5M for any trailing twelve-month period (Q3 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Zephyr Valve | severe emphysema / COPD | device-combination | Approved |
| Chartis System | patient assessment for emphysema treatment | device-combination | Approved |
| LungTraX Platform | patient identification for Zephyr Valve treatment | device-combination | Approved |
| AeriSeal System | severe emphysema patients with excessive collateral ventilation (not qualified for Zephyr Valve) | device-combination | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 respiratory companies
- Bristol Myers Squibb Co BMY
- INSMED Inc INSM
- Liquidia Corp LQDA
- Trevi Therapeutics, Inc. TRVI
- Generate Biomedicines, Inc. GENB
- Savara Inc SVRA
- Apnimed, Inc. APMD
- Inhibikase Therapeutics, Inc. IKT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.